Bruton Tyrosine Kinase (BTK) Inhibitors in Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

EP. 1: Dr. Kumar on Treatment Options for Patients Who Progress on a BTK Inhibitor in MCL

August 3rd 2022

Anita Kumar, MD, discusses treatment options for patients with mantle cell lymphoma who progress on BTK inhibitors.

EP. 2: Dr. Lunning on Trials Evaluating BTK Inhibitors in CLL

August 3rd 2022

Matthew A. Lunning, DO, FACP, discusses trials evaluating BTK inhibitors in chronic lymphocytic leukemia.

EP. 3: Dr. Maddocks on the Investigation of Noncovalent BTK Inhibitors in MCL

August 3rd 2022

Kami J. Maddocks, MD, discusses the investigation of noncovalent BTK inhibitors in mantle cell lymphoma.

EP. 4: Dr. Danilov on the Future of BTK Inhibitors in CLL

August 10th 2022

Alexey V. Danilov, MD, PhD, discusses the future of BTK inhibitors in chronic lymphocytic leukemia.

EP. 5: The Role of Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

October 11th 2022

A select group of hematologic oncologists participated in a virtual workshop to discuss the role of BTK inhibitors in the treatment of MCL and CLL Led by Kami Maddocks, MD; and Anthony Mato, MD. The expert panel shared insights on the available evidence regarding BTK inhibitors in MCL and CLL, novel treatment approaches, and optimal strategies for combining and sequencing therapies.

EP. 6: Dr. Owen on Choosing Between BTK Inhibitors in CLL

March 8th 2023

Carolyn Owen, MD, FRCPC, discusses factors to consider when deciding whether to use the BTK inhibitors ibrutinib, acalabrutinib, or zanubrutinib in patients with chronic lymphocytic leukemia.

EP. 7: Dr. Torka on the Role of Pirtobrutinib in R/R MCL

March 8th 2023

Pallawi Torka, MD, discusses the clinical implications of the FDA approval of pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma.

EP. 8: BTK Inhibitors in MCL and CLL

March 10th 2023

EP. 9: Dr. Phillips on BTK Inhibitor Selection in MCL

March 15th 2023

Tycel Phillips, MD, MPH, discusses how to approach selecting BTK inhibitors for patients with mantle cell lymphoma and treatment decisions following disease progression on a BTK inhibitor.